Amphastar Pharmaceuticals announces an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for a fully synthetic corticotropin compound designated AMP-110.
The agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions.
AMP-110 is designed to address inflammatory and autoimmune conditions with a potentially improved safety profile compared to porcine-derived ACTH products.
Strategic Addition to Portfolio
AMP-110 represents a strategically important addition to Amphastar's growing proprietary peptide portfolio with the potential for a differentiated safety profile.
Financial Terms
Amphastar made an upfront payment of $2 million to Hanxin, with additional milestone and sales payments totaling up to $89 million. Royalty agreements are also in place.
Clinical Development
AMP-110 is currently in early-phase human clinical development with promising safety results. It aims to target a market exceeding $684 million annually for various indications.
- The exclusive agreement with Hanxin provides Amphastar with access to a fully synthetic compound for addressing a wide range of inflammatory and autoimmune conditions.
- AMP-110's potential improved safety profile positions Amphastar well in the therapeutic category and aligns with its long-term vision for innovative proprietary products.
The partnership with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. marks a significant milestone for Amphastar Pharmaceuticals, enhancing its peptide portfolio and paving the way for addressing critical healthcare needs in inflammatory and autoimmune conditions.